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,e National Comprehensive Cancer Network expanded their lung cancer screening (LCS) criteria to comprise one additional
clinical risk factor, including chronic obstructive pulmonary disease (COPD). ,e electronic medical record (EMR) is a source of
clinical information that could identify high-risk populations for LCS, including a diagnosis of COPD; however, an unsub-
stantiated COPD diagnosis in the EMR may lead to inappropriate LCS referrals. We aimed to detect the prevalence of un-
substantiated COPD diagnosis in the EMR for LCS referrals, to determine the efficacy of utilizing the EMR as an accurate
population-based eligibility screening “trigger” using modified clinical criteria. We performed a multicenter review of all in-
dividuals referred to three LCS programs from 2012 to 2015. Each individual’s EMR was searched for COPD diagnostic terms and
the presence of a diagnostic pulmonary functionality test (PFT). An unsubstantiated COPD diagnosis was defined by an in-
dividual’s EMR containing a COPD term with no PFTs present, or the presence of PFTs without evidence of obstruction. A total of
2834 referred individuals were identified, of which 30% (840/2834) had a COPD term present in their EMR. Of these, 68% (571/
840) were considered unsubstantiated diagnoses: 86% (489/571) due to absent PFTs and 14% (82/571) due to PFTs demonstrating
no evidence of postbronchodilation obstruction. A large proportion of individuals referred for LCS may have an unsubstantiated
COPD diagnosis within their EMR. ,us, utilizing the EMR as a population-based eligibility screening tool, employing expanded
criteria, may lead to individuals being referred, potentially, inappropriately for LCS.
1. Introduction
As lung cancer screening programs (LCSPs) proliferate
outside the research environment, debate regarding the
optimal population for screening continues. Fodder for this
debate comes from advocates and societies which recom-
mend expanding lung cancer screening (LCS) criteria to
individuals with a lung cancer risk based on clinical factors
other than smoking and age [1, 2]. While medical society
guidelines hue close to the Center for Medicare and Med-
icaid Services inclusion criteria, the National Comprehen-
sive Cancer Network (NCCN) and the American
Association for ,oracic Surgery (AATS) recommend
modified risk criteria. ,ese criteria allow for a decrease in
both age and tobacco pack year when a diagnosis of chronic
lung disease, including chronic obstructive pulmonary
disease (COPD), is present. COPD is an independent risk
factor for lung cancer, but it is often misclassified and
unsubstantiated in the medical record [3–8].
,e electronic medical record (EMR) is used as a
population-based screening tool by hospitals and healthcare
networks for identification of at-risk populations, including
lung cancer screening. ,ese EMR “triggers” or best practice
alerts (BPA) draw from predetermined, autopopulated EMR
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fields, which are dependent on the quality of the entered
data. Inaccurate data used to trigger the BPA and prompt
LCS could result in inappropriate populations being
screened, potentially impacting the balance of benefits
versus harms as LCSPs proliferate.
We aimed to detect the prevalence of unsubstantiated
COPD diagnosis in the EMR of individuals referred for LCS,
to determine the efficacy of utilizing the EMR as an accurate
population-based eligibility screening “trigger” using
modified clinical criteria.
2. Materials and Methods
2.1. Study Population. We reviewed individuals who were
referred to three separate LCSPs between January 1, 2012,
and February 29, 2016. ,e LCSPs included were
those based on the Swedish Cancer Institute in Seattle,
Washington State; Providence Regional Cancer Partner-
ship in Everett, Washington State; and Providence Health
and Services in Portland, Oregon. Data from all indi-
viduals referred to the three LCSPs were pooled and
is presented as such. ,e Swedish Cancer Institute
Institutional Review Board approved this study
(SWD5896S-15) and provided coverage for the other
affiliated sites, and the requirement for informed consent
was waived.
2.2. Electronic Medical Record Review. Each individual’s
EMR (EPIC Hyperspace Version 6.0, Verona, Wisconsin)
was searched for the obstructive pulmonary disease terms
“COPD and chronic airway obstruction,” as well as “chronic
bronchitis and emphysema” as these terms are often
interchanged with COPD terms. ,e first location where the
term was identified in the EMR, as well as the specialty/title
of the individual who entered the term, was captured.
To determine if the presence of the term in the individual’s
EMR as a diagnosis was substantiated, we searched for
the presence of a confirmatory pulmonary function test
(PFT).
2.3. Substantiated versus Unsubstantiated Diagnosis. A
substantiated COPD diagnosis was defined by the presence
of a confirmatory PFT as per the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria: a
postbronchodilator FEV1/FVC< 0.70 [9].
A diagnosis was considered unsubstantiated when an
obstructive term was present in an individual’s EMR with
either no PFTs present (even if mentioned as previously
performed), or when PFTs were present that were negative
or without evidence of sustained postbronchodilation
obstruction.
2.4. Statistical Analysis. Data are reported as counts and
percentages, as well as median and 25th–75th interquartile
ranges. Data summary was performed in Microsoft Excel
(Microsoft Office 2013; Redmond, Washington).
3. Results
We identified a total of 2834 referred individuals, of which
the median age was 63 years (IQR: 59–68) and 53% (1510)
were male.
3.1. Obstructive Terms Present, Unsubstantiated Diagnosis.
An obstructive pulmonary disease term was present in 30%
(840/2834) of referred individual’s EMRs (Figure 1). Of
these, 68% (571/840) were considered unsubstantiated di-
agnoses: 86% (489/571) due to absence of a PFTand 14% (82/
571) due to a PFT demonstrating no evidence of post-
bronchodilation obstruction. ,us, 20% (571/2834) of the
total referred population had an unsubstantiated diagnosis.
Ninety-one percent (521/571) of individuals had a di-
agnosis with at least the term “obstructive,” while 4% (20/
571) and 5% (30/571) had the isolated terms “chronic
bronchitis” and “emphysema,” respectively.
,e most prominent locations in the EMR where the
unsubstantiated term was first identified was the “problem
list” (83%, 473/571) and the “history” tab (16%, 89/571).
Only a minority had terms identified within notes in the
chart (1%, 9/571).
,e most frequent specialty of individuals entering an
unsubstantiated term in the EMR was family medicine
(Figure 2).
3.2. Obstructive Terms Present, Substantiated Diagnosis.
Of those with obstructive terms present, 32% (269/840) had
confirmation of their COPD diagnosis with positive PFTs
present in the EMR (Figure 1).
3.3. NoObstructive Terms Present. Of those referrals with no
obstructive terms present in their EMR (70%, 1994/2834),
the majority had either no PFTs present (89%, 1771/1994) or
a negative PFT (8%, 166/1994), while 3% (57/1994) had PFTs
diagnostic of COPD (Figure 1).
4. Comment
,is is one of the first studies to address the challenges posed
by EMR-identified high-risk individuals for LCS using
modified clinical criteria in a large population of screened
individuals from multiple centers. We identified that 20% of
all individuals referred for LCS had an unsubstantiated
diagnosis of obstructive airway disease within their EMR.
,e integrity of clinical data on COPDwithin the EMR poses
a potential challenge to identification of an alternative risk
population eligible for LCS based on the clinical diagnosis of
COPD as proposed by the NCCN expanded criteria.
Although it is often quoted that the number needed to
screen to prevent one lung cancer death is 320, further
analysis of the NLST demonstrated that screening risk is
more nuanced and there is variable risk within that pop-
ulation [8, 10]. ,e results of the analysis confirmed that
tailoring of low-dose CT screening to a patient’s predicted
risk of lung cancer death could narrow the eligible pop-
ulation without loss of the benefits of screening or a
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disproportionate increase in harms [10]. By restricting
screening to the 60% of participants at the highest risk for
death from lung cancer within five years (the three highest
quintiles of risk of the five), as compared with the entire
group, 88% of preventable lung cancer deaths were captured,
the number of participants needed to be screened to prevent
one lung cancer death was reduced from 302 to 161, and the
number of false positive results per prevented lung cancer
death was reduced from 108 to 65. Efforts to better define
individuals and populations at risk are active areas of study.
Not all screening trials have demonstrated a survival benefit
as seen in the NLST. Both the Detection And screening of
early lung cancer with Novel imaging Technology (DANTE)
trial and the Danish Lung Cancer Screening Trial (DLCST)
failed to show a lung cancer survival advantage through
screening [11, 12]. One possible explanation for this is
reduced eligibility criteria of age (60–74 years for the
DANTE trial and 50–70 years for the DLCST trial) and
tobacco exposure (minimum of 20 pack-years of smoking),
reducing the screened populations risk and potentially
missing the benefit of screening [13, 14].
,e NCCN and AATS have published modified criteria
for LCS in individuals with pulmonary disease, specifically
pulmonary fibrosis and COPD, and while smoking is the
leading risk factor for the development of lung cancer, it is
also the leading contributor to COPD, so it is logical that
overlap between the two exists [6, 7]. Studies suggest that
COPD affects nearly a quarter of smokers and is reported in
40–80% of smoking-related lung cancer patients [15–18].
Historically, studies reported on the intimate relationship
between the incidence and clinical course of lung cancer and
COPD, suggesting COPD may only be a risk factor for lung
cancer; however, more recently, many cohort studies, in-
cluding LCS trials, have demonstrated a 2–4 times greater
risk of incident lung cancer in individuals with COPD/
emphysema compared to those without [5, 19–21]. In ad-
dition, a recent study suggested a linear relationship between
the severity of COPD and incidence of lung cancer, with the
risk of lung cancer correlating to increasing GOLD classi-
fication, independent of cigarette smoking status [22].
Our data demonstrate that 20% of our population did
not have a substantiated diagnosis of COPD. ,e misdi-
agnosis of obstructive lung disease is not a new one, and
other studies of both COPD and asthma have demonstrated
misdiagnosis and/or lack of substantiated diagnosis
[16, 23–26]. ,e diagnosis of COPD remains based on the
documentation of irreversible airflow obstruction, devel-
oped to determine disease severity, as well as to help avoid
misdiagnosis [9]. A recent Veterans Affairs health system
study of hospitalized patients demonstrated that 21% had no
spirometric measurements and 11% had normal pre- or
postbronchodilator measurements, despite a discharge di-
agnosis of COPD [27]. In addition, a Canadian report from
three primary care sites demonstrated that 21% of patients
over 40 years with a minimum smoking history of 20 pack-
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Figure 1: Flow diagram depicting lung cancer screening program referrals stratified by the presence or absence of pulmonary airway
obstructive terms in the individual’s electronic medical record and whether these were substantiated.
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Figure 2: Specialty/title of the individuals who entered an un-
substantiated pulmonary airway obstructive term.
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years had spirometry consistent with COPD, but only 30% of
these individuals had been correctly diagnosed with COPD
prior to the study [28]. Similarly, other studies have reported
variable rates of spirometry confirming COPD that range
from 9 to 70% [23–26]. In addition, the prevalence of COPD
in the US surveillance data from 1999 to 2011 was based in-
part on the Behavioral Risk Factor Surveillance System and
in-part on the National Health Interview Survey [29]. In
both these surveys, the definition of COPD was based on
responses to the survey questions: have you ever been told by
a doctor or other health professional that you have COPD,
emphysema, or chronic bronchitis?
It is well established that LCS of high-risk individuals
with low-dose CT demonstrates a mortality benefit [8].
However, despite recommendations, only a relatively small
proportion of eligible individuals are currently being
screened, as evidenced by low numbers of program enrollees
relative to the estimated 7 million individuals in the US who
would meet eligibility criteria [8, 30]. While multiple in-
terventions will be required to target this challenge, a so-
lution currently being explored is the mass identification of
high-risk individuals through population-based eligibility
screening utilizing the EMR [31]. ,e EMR is the principle
source of relevant clinical information and is increasingly
used for management of chronic disease such as COPD
[32, 33].
While this concept of identifying eligible individuals with a
population-based screening tool, such as an EMR search, is
attractive; in reality, this should be approached with caution as
data reliability has been shown to be unpredictable. We
previously demonstrated that data entered into the EMR is not
necessarily accurate, as we identified that there was a 96%
discordance rate in the pack-year smoking history obtained
from the EMR versus the shared decision-making conversa-
tion at the time of LCS [34]. Other studies have reported
similar concerns. A recent study identified that the sensitivity
of the problem list for identifying common major comor-
bidities, including COPD, was poor and ranged from 1 to 46%
[35]. In addition, a report of EMR triage medication history
recorded on emergency department visits identified accuracy
in only 22% of cases, and a separate report assessing EMRs
accompanying referral requests by physicians for plastic
surgery consultation identified frequent inaccuracies and in-
complete data fields [36, 37].
,ere are several limitations to this study. First, the
retrospective study design is associated with an inherent
bias. Second, we did not attempt to investigate if PFTs were
performed at an outside institution if the diagnosis of COPD
was made prior to the individual coming into contact with
our system. However, missing this information was likely
minimized as previous notes should be scanned into the
EMR on referral. Lastly, geographic clustering of COPD
prevalence, medicare hospitalizations, and COPD-related
mortality has been reported, particularly along the Ohio
River Valley and several Western and Southern States [29].
,is regional variation in COPD burden could limit the
generalizability of our results.
In conclusion, this study demonstrates that a large
proportion of individuals referred to LCSPs may have an
unsubstantiated diagnosis of COPD within their EMR.
Utilization of the EMR as a population-based eligibility
screening tool may lead to a significant proportion of in-
dividuals being inappropriately referred for LCS. Utilization
of expanded criteria, adding the clinical diagnosis of COPD
and lowering the eligibility age and tobacco pack-year, to
broaden the risk pool may be challenged by a high rate of
unsubstantiated diagnosis. Careful review of charts and
accurate documentation, as well as employment of more
objective metrics to refine the high-risk populations for LCS
referral, is needed.
Abbreviation
AATS: American Association for ,oracic Surgery
CMS: Centers for Medicare and Medicaid Services
COPD: Chronic obstructive pulmonary disease
CT: Computed tomography
DANTE: Detection And screening of early lung cancer with
Novel imaging Technology
DLCST: Danish Lung Cancer Screening Trial
EMR: Electronic medical record
FEV1: Forced expiratory volume in one second
FVC: Forced vital capacity
GOLD: Global Initiative for Chronic Obstructive Lung
Disease
LCS: Lung cancer screening
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NCCN: National Comprehensive Cancer Network
NLST: National Lung Screening Trial
PFT: Pulmonary function test
US: United States.
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